PMID- 32321394
OWN - NLM
STAT- MEDLINE
DCOM- 20210319
LR  - 20220531
IS  - 1873-4286 (Electronic)
IS  - 1381-6128 (Linking)
VI  - 26
IP  - 38
DP  - 2020
TI  - Bisphosphonates Can Maintain Periprosthetic Bone Mass Density after Total Hip 
      Replacement, with Controversy in Region of Interest 5.
PG  - 4925-4933
LID - 10.2174/1381612826666200422093213 [doi]
AB  - BACKGROUND: Total hip replacement (THR) is the standard surgical treatment of hip 
      diseases. Periprosthetic bone mass density (BMD) loss may be a cause for revision 
      surgery. Bisphosphonates (BPs) are now the principal class medications for 
      osteoporosis. OBJECTIVE: To demonstrate the effect of BPs on treating 
      periprosthetic osteoporosis after THR via a meta-analysis of randomized 
      controlled trials (RCTs). METHODS: A comprehensive search of PubMed, EMBASE, the 
      Web of Science and the Cochrane Central Register of Controlled Trials was 
      performed for RCTs on the effect of BPs on treating periprosthetic osteoporosis 
      after THR and clinical outcomes relative to controls. The primary outcome 
      measures were the change in BMD in each region of interest (ROI), the change in 
      serum bone turnover marker levels, the change in functional parameters and the 
      risk of adverse effects (AEs). The final search was performed in March, 2020. 
      RESULTS: Nine RCTs were included. A total of 359 patients met the inclusion 
      criteria. BPs can clearly maintain periprosthetic BMD in ROIs at 1, 2, 3, 4, 6 
      and 7 at 6, 12 and 24 months. In addition, BPs can clearly decrease serum 
      procollagen type 1 N-terminal propeptide (P1NP) levels at 12 months. There was no 
      significant difference in the risk of AEs between the BP and control groups; 
      however, BPs can cause more patients to decline participation. CONCLUSION: BPs 
      can effectively maintain overall periprosthetic BMD, but BMD in ROI 5 remains 
      controversial. In addition, the safety of BPs is relatively high, but the 
      compliance may be relatively low.
CI  - Copyright(c) Bentham Science Publishers; For any queries, please email at 
      epub@benthamscience.net.
FAU - Hao, Dongsheng
AU  - Hao D
AD  - Shanxi Bethune Hospital, Taiyuan, Shanxi Province, China.
FAU - Wang, Junjie
AU  - Wang J
AD  - Changzhi Medical College, Changzhi, Shanxi, China.
FAU - Zuo, Liyun
AU  - Zuo L
AD  - Medical College of Shanxi Datong University, Datong, Shanxi, China.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Systematic Review
PL  - United Arab Emirates
TA  - Curr Pharm Des
JT  - Current pharmaceutical design
JID - 9602487
RN  - 0 (Bone Density Conservation Agents)
RN  - 0 (Diphosphonates)
SB  - IM
EIN - Curr Pharm Des. 2020;26(41):5362. PMID: 33504291
MH  - *Arthroplasty, Replacement, Hip
MH  - Bone Density
MH  - *Bone Density Conservation Agents
MH  - Diphosphonates
MH  - Humans
MH  - *Osteoporosis
OTO - NOTNLM
OT  - Bisphosphonates
OT  - meta-analysis
OT  - osteoporosis
OT  - propeptide
OT  - randomized controlled trials
OT  - total hip replacement
EDAT- 2020/04/24 06:00
MHDA- 2021/03/20 06:00
CRDT- 2020/04/24 06:00
PHST- 2020/01/21 00:00 [received]
PHST- 2020/04/01 00:00 [accepted]
PHST- 2020/04/24 06:00 [pubmed]
PHST- 2021/03/20 06:00 [medline]
PHST- 2020/04/24 06:00 [entrez]
AID - CPD-EPUB-105997 [pii]
AID - 10.2174/1381612826666200422093213 [doi]
PST - ppublish
SO  - Curr Pharm Des. 2020;26(38):4925-4933. doi: 10.2174/1381612826666200422093213.